Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with
cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.